Suzanne J Baron1,2, Kaijun Wang2, Suzanne V Arnold2, Elizabeth A Magnuson2, Brian Whisenant3, Andreas Brieke4, Michael Rinaldi5, Anita W Asgar6, Joann Lindenfeld7, William T Abraham8, Michael J Mack9, Gregg W Stone10, David J Cohen11. 1. Lahey Hospital and Medical Center, Burlington, MA (S.J.B.). 2. Saint Luke's Mid America Heart Institute, Kansas City, MO (S.J.B., K.W., S.V.A., E.A.M.). 3. Intermountain Heart Institute, Salt Lake City, UT (B.W.). 4. University of Colorado Hospital, Aurora (A.B.). 5. Sanger Heart and Vascular Institute, Atrium Health, Charlotte, NC (M.R.). 6. Montreal Heart Institute, QC, Canada (A.W.A.). 7. Vanderbilt University Medical Center, Nashville, TN (J.L.). 8. Davis Heart and Lung Research Institute, Ohio State University, Columbus (W.T.A.). 9. Baylor Scott and White Healthcare, Plano, TX (M.J.M.). 10. Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.). 11. University of Missouri-Kansas City (D.J.C.).
Abstract
BACKGROUND: The COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) with the MitraClip resulted in reduced mortality and heart failure hospitalizations and improved quality of life compared with maximally tolerated guideline-directed medical therapy (GDMT) in patients with heart failure and 3 to 4+ secondary mitral regurgitation. Whether TMVr is cost-effective compared with GDMT in this population is unknown. METHODS: We used data from the COAPT trial to perform a formal patient-level economic analysis of TMVr+GDMT versus GDMT alone for patients with heart failure and 3 to 4+ secondary mitral regurgitation from the perspective of the US healthcare system. Costs for the index TMVr hospitalization were assessed using a combination of resource-based accounting and hospital billing data (when available). Follow-up medical care costs were estimated on the basis of medical resource use collected during the COAPT trial. Health utilities were estimated for all patients at baseline and 1, 6, 12, and 24 months with the Short Form Six-Dimension Health Survey. RESULTS: Initial costs for the TMVr procedure and index hospitalization were $35 755 and $48 198, respectively. Although follow-up costs were significantly lower with TMVr compared with GDMT ($26 654 versus $38 345; P=0.018), cumulative 2-year costs remained higher with TMVr because of the upfront cost of the index procedure ($73 416 versus $38 345; P<0.001). When in-trial survival, health utilities, and costs were modeled over a lifetime horizon, TMVr was projected to increase life expectancy by 1.13 years and quality-adjusted life-years by 0.82 years at a cost of $45 648, yielding a lifetime incremental cost-effectiveness ratio of $40 361 per life-year gained and $55 600 per quality-adjusted life-year gained. CONCLUSIONS: For symptomatic patients with heart failure and 3 to 4+ secondary mitral regurgitation, TMVr increases life expectancy and quality-adjusted life expectancy compared with GDMT at an incremental cost per quality-adjusted life-year gained that represents acceptable economic value according to current US thresholds. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01626079.
BACKGROUND: The COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart FailurePatients With Functional Mitral Regurgitation) demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) with the MitraClip resulted in reduced mortality and heart failure hospitalizations and improved quality of life compared with maximally tolerated guideline-directed medical therapy (GDMT) in patients with heart failure and 3 to 4+ secondary mitral regurgitation. Whether TMVr is cost-effective compared with GDMT in this population is unknown. METHODS: We used data from the COAPT trial to perform a formal patient-level economic analysis of TMVr+GDMT versus GDMT alone for patients with heart failure and 3 to 4+ secondary mitral regurgitation from the perspective of the US healthcare system. Costs for the index TMVr hospitalization were assessed using a combination of resource-based accounting and hospital billing data (when available). Follow-up medical care costs were estimated on the basis of medical resource use collected during the COAPT trial. Health utilities were estimated for all patients at baseline and 1, 6, 12, and 24 months with the Short Form Six-Dimension Health Survey. RESULTS: Initial costs for the TMVr procedure and index hospitalization were $35 755 and $48 198, respectively. Although follow-up costs were significantly lower with TMVr compared with GDMT ($26 654 versus $38 345; P=0.018), cumulative 2-year costs remained higher with TMVr because of the upfront cost of the index procedure ($73 416 versus $38 345; P<0.001). When in-trial survival, health utilities, and costs were modeled over a lifetime horizon, TMVr was projected to increase life expectancy by 1.13 years and quality-adjusted life-years by 0.82 years at a cost of $45 648, yielding a lifetime incremental cost-effectiveness ratio of $40 361 per life-year gained and $55 600 per quality-adjusted life-year gained. CONCLUSIONS: For symptomatic patients with heart failure and 3 to 4+ secondary mitral regurgitation, TMVr increases life expectancy and quality-adjusted life expectancy compared with GDMT at an incremental cost per quality-adjusted life-year gained that represents acceptable economic value according to current US thresholds. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01626079.
Authors: Paul A Heidenreich; Gregg C Fonarow; Yekaterina Opsha; Alexander T Sandhu; Nancy K Sweitzer; Haider J Warraich Journal: J Card Fail Date: 2022-01-24 Impact factor: 6.592
Authors: Maria Winte; Krysta Contino; Aditi Trivedi; Nikhita Dharbhamulla; John Gaughan; Christopher Deitch; Sangita Phadtare Journal: Ann Med Surg (Lond) Date: 2020-08-06
Authors: Parth K Modi; Samuel R Kaufman; Megan Ev Caram; Andrew M Ryan; Vahakn B Shahinian; Brent K Hollenbeck Journal: J Am Coll Surg Date: 2020-10-26 Impact factor: 6.113
Authors: Waqas Ullah; Yasar Sattar; Maryam Mukhtar; Hafez M Abdullah; Vincent M Figueredo; Donald C Haas; David L Fischman; M Chadi Alraies Journal: Int J Cardiol Heart Vasc Date: 2020-05-28
Authors: Andrew J S Coats; Stefan D Anker; Andreas Baumbach; Ottavio Alfieri; Ralph Stephan von Bardeleben; Johann Bauersachs; Jeroen J Bax; Serge Boveda; Jelena Čelutkienė; John G Cleland; Nikolaos Dagres; Thomas Deneke; Dimitrios Farmakis; Gerasimos Filippatos; Jörg Hausleiter; Gerhard Hindricks; Ewa A Jankowska; Mitja Lainscak; Christoph Leclercq; Lars H Lund; Theresa McDonagh; Mandeep R Mehra; Marco Metra; Nathan Mewton; Christian Mueller; Wilfried Mullens; Claudio Muneretto; Jean-Francois Obadia; Piotr Ponikowski; Fabien Praz; Volker Rudolph; Frank Ruschitzka; Alec Vahanian; Stephan Windecker; Jose Luis Zamorano; Thor Edvardsen; Hein Heidbuchel; Petar M Seferovic; Bernard Prendergast Journal: Eur Heart J Date: 2021-03-18 Impact factor: 29.983
Authors: David J Cohen; Kaijun Wang; Elizabeth Magnuson; Robert Smith; Mark C Petrie; Mamta Heena Buch; William Abraham; Joann Lindenfeld; Michael J Mack; Gregg W Stone; John G F Cleland Journal: Heart Date: 2022-01-25 Impact factor: 7.365
Authors: Faizus Sazzad; Jimmy Kim Fatt Hon; Kollengode Ramanathan; Jie Hui Nah; Zhi Xian Ong; Lian Kah Ti; Roger Foo; Edgar Tay; Theo Kofidis Journal: Front Cardiovasc Med Date: 2022-02-24